Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: A prospective, population-based study

Annals of Oncology

Volumn 20, Issue 1, 2009, Pages 98-102

  De Ruysscher, Dirk K M ^a   Botterweck, A ^b   Dirx, M ^b   Pijls Johannesma, M ^c   Wanders, R ^c   Hochstenbag, M ^a   Dingemans, A M C ^a   Bootsma, G ^d   Geraedts, W ^d   Simons, J ^f   Pitz, C ^e   Lambin, P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Maastricht UMC+ Comprehensive Cancer Centre   (Netherlands)

^c MAASTRO CLINIC   (Netherlands)

^d Sittard Geleen Heerlen   (Netherlands)

^e LAURENTIUS HOSPITAL   (Netherlands)

^f Maasland Hospital ^*  (Netherlands)

Author keywords

Combined modality treatment; Comorbidity; Concurrent chemotherapy and radiotherapy; Lung cancer; Maastricht Cancer Registry

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMORBIDITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PATIENT SELECTION; POPULATION; REGISTRIES; YOUNG ADULT;

EID: 58949103085     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn559     Document Type: Article

References (34)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
2. Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francxais de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005; 23: 5910-5917.
3. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
4. Curran WJ, Scott CB, Langer CJ et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III NSCLC: RTOG 94-10. Proc Am Soc Clin Oncol 2003; 621a (Abstr 2499).
5. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced nonsmall cell lung cancer: A randomized study. Lung Cancer 2004; 46: 87-98.
6. Rowell NP, O'rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; (4): CD002140.
7. Auperin A, Rolland E, Curran W Jr et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2007; 2 (Suppl 4): S310 (Abstr A1-A05).
8. Turrisi AT, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-271.
9. Takada M, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20: 3054-3060.
10. Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22: 4785-4793.
11. Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J et al. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 2007; 33: 461-473.
12. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 1057-1063.
13. Robinson LA, Ruckdeschel JC, Wagner H Jr et al. American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines 2nd edition. Chest 2007; 132: 243S-265S.
14. Jett JR, Schild SE, Keith RL et al. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines 2nd edition. Chest 2007; 132: 266S-276S.
15. Mayor S. NICE issues guidance for diagnosis and treatment of lung cancer. BMJ 2005; 330: 439.
16. Janssen-Heijnen ML, Schipper RM, Razenberg PP et al. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21: 105-113.
17. van de Schans SA, Janssen-Heijnen ML, Biesma B et al. COPD in cancer patients: Higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient. Eur J Cancer 2007; 43: 2194-2202.
18. Janssen-Heijnen ML, Lemmens VE, van den Borne BE et al. Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: A population-based study in the Netherlands. Crit Rev Oncol Hematol 2007; 62: 172-178.
19. Vulto AJ, Lemmens VE, Louwman MW et al. The influence of age and comorbidity on receiving radiotherapy as part of primary treatment for cancer in South Netherlands, 1995 to 2002. Cancer 2006; 106: 2734-2742.
20. Janssen-Heijnen ML, Smulders S, Lemmens VE et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004; 59: 602-607.
21. Gridelli C, Langer C, Maione P et al. Lung cancer in the elderly. J Clin Oncol 2007; 25: 1898-1907.
22. Lilenbaum RC, Cashy J, Hensing TA et al. Prevalence of poor performance status in lung cancer patients: Implications for research. J Thorac Oncol 2008; 3: 125-129.
23. World Health Organization. International Classification of Diseases for Oncology (ICD-O-3), 3rd edition. Geneva: WHO Press 2000.
24. Sobin LH, Wittekind Ch (eds). International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 6th edition. New York: Wiley-Liss 2002.
25. Schouten LJ, Hoppener P, van den Brandt PA et al. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 369-376.
26. Charlson M, Szatrowski TP, Peterson J et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
27. Radiation Therapy Oncology Group. RTOG 0617/NCCTG N0628/CALGB 30609 A randomzed phase III comparison of standard-dose (60 Gy) versus high dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel in patients with stage IIIA/IIIB non-small cell lung cancer. http://www.rtog.org/members/protocols/0617/0617.pdf. (22 May 2008, date last accessed).
28. Asmis TR, Ding K, Seymour L et al. National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008; 26: 54-59.
29. Firat S, Pleister A, Byhardt RW et al. Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol 2006; 29: 252-257.
30. Read WL, Tierney RM, Page NC et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22: 3099-3103.
31. Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25: 5570-5577.
32. van Baardwijk A, Bosmans G, Boersma L et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: A feasibility study. Int J Radiat Oncol Biol Phys 2008; 71: 1103-1110.
33. Brada M, Pijls-Johannesma M, De Ruysscher D. Proton therapy in clinical practice: Current clinical evidence. J Clin Oncol 2007; 25: 965-970.
34. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24: 5253-5258.